Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Linear Formula:
(ClC6H4)2CHCHCl2
CAS Number:
Molecular Weight:
320.04
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
NACRES:
NA.24
EC Number:
200-166-6
Beilstein/REAXYS Number:
2056007
InChI key
JWBOIMRXGHLCPP-UHFFFAOYSA-N
InChI
1S/C14H10Cl4/c15-10-7-5-9(6-8-10)13(14(17)18)11-3-1-2-4-12(11)16/h1-8,13-14H
SMILES string
ClC(Cl)C(c1ccc(Cl)cc1)c2ccccc2Cl
grade
analytical standard
product line
PESTANAL®
shelf life
limited shelf life, expiry date on the label
technique(s)
HPLC: suitable, gas chromatography (GC): suitable
application(s)
agriculture
environmental
format
neat
Quality Level
Gene Information
human ... CYP11A1(1583), CYP11B1(1584)
Related Categories
General description
2,4′-DDD is generally used to reduce the endogenous CORT neuropeptide, which might mask the total population of intracellular corticosteroid receptors in sparrows. It is an adrenal specific agent, which can find potent applications in the treatment of adrenocortical carcinoma (ACC).
Application
Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.
Legal Information
PESTANAL is a registered trademark of Merck KGaA, Darmstadt, Germany
signalword
Warning
hcodes
Hazard Classifications
Carc. 2
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients
Haak.R.H, et al.
British Journal of Cancer, 69(5), 947-951 (1994)
Pharmacological characterization of intracellular, membrane, and plasma binding sites for corticosterone in house sparrows
Breuner.WC and Orchinik M
General and Comparative Endocrinology, 163(1), 214-224 (2009)
Mitotane for adrenocortical carcinoma treatment
SH and MF
Current Opinion in Investigational Drugs, 6(4), 386-394 (2005)
Vasileios Chortis et al.
The Journal of clinical endocrinology and metabolism, 98(1), 161-171 (2012-11-20)
Mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane] is the first-line treatment for metastatic adrenocortical carcinoma (ACC) and is also regularly used in the adjuvant setting after presumed complete removal of the primary tumor. Mitotane is considered an adrenolytic substance, but there is limited information on
Matthias Kroiss et al.
The Journal of clinical endocrinology and metabolism, 97(10), 3495-3503 (2012-07-28)
Treatment of refractory adrenocortical carcinoma (ACC) is not established. Animal experiments pointed toward adrenal toxicity of sunitinib. The objective of the study was to determine the antitumor effects of sunitinib in refractory ACC. This was a phase II, open-label trial
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service